Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PM Reiterates Support for Stock Companies' Management of Medical Facilities: Diet
December 23, 2002
- Toho Pharmaceutical Listed on TSE
December 23, 2002
- < Opening Remarks at the December 6 Press Conference >
December 23, 2002
- BUSINESS NEWS IN BRIEF
December 23, 2002
- Deregulation Panel Supports Sale of Less-risk Drugs by General Retailers
December 23, 2002
- 2,000 MRs from Yamanouchi, NBI Promote Micardis
December 23, 2002
- BT Strategy Policy Compiled
December 23, 2002
- Fujisawa: Japan's 1st Candin Antifungal Funguard
December 23, 2002
- Decision on Stock Companies' Management of Medical Institutions Remains Unpredictable
December 23, 2002
- NEW PRODUCTS IN BRIEF
December 23, 2002
- Bill on New Drug Organization Clears the Diet
December 23, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 23, 2002
- No Meaningful Progress on Mutual Recognition: MOSS Follow-up Talks
December 23, 2002
- OTC NEWS IN BRIEF
December 23, 2002
- Strong Incentives Essential to Development of Innovative Drugs: CEFP
December 23, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 23, 2002
- REGULATORY NEWS IN BRIEF
December 23, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 23, 2002
- Tracheal Intubation by Lifeguards to Be Permitted from July 2004
December 23, 2002
- EFPIA Wishes to Actively Participate in Japanese Healthcare Reform Talks
December 23, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…